Market ExpansionIf successful in obtaining a label expansion for Increlex, the eligible patient population could grow from approximately 200 to 1,000, significantly boosting potential revenue.
Product LaunchEton Pharmaceuticals is on track to launch ET-400, a hydrocortisone oral solution, which is expected to address issues with the current granule texture and drive robust adoption.
Revenue GrowthManagement projects peak combined revenue of ET-400 and ALKINDI SPRINKLE to exceed $50 million annually.
Strategic AcquisitionsRecent acquisitions of Galzin, Increlex, and Amglidia are expected to be major revenue drivers in the near and long term.